Who Owns Iovance Biotherapeutics Stock?
NASDAQ: IOVAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 69.15%
- Held by insiders
- 0.82%
- Institutional holders
- 428
- Institutions 69.2%
- Insiders 0.8%
- Public and other 30.0%
Who owns Iovance Biotherapeutics stock?
Institutional investors own about 69.2% of Iovance Biotherapeutics's shares, spread across 428 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 0.82% of IOVA.
The largest institutional holders are Blackrock Inc. (8.19%), MHR Fund Management, LLC (6.26%) and State Street Corporation (4.69%). Together, the top 10 institutions control 36.5% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their IOVA positions and 5 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of IOVA
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 37.90M | 8.19% | +2.6% |
| MHR Fund Management, LLC | 28.97M | 6.26% | 0.0% |
| State Street Corporation | 21.70M | 4.69% | -11.4% |
| Two Sigma Investments, LP | 19.01M | 4.11% | +38.9% |
| Vanguard Capital Management LLC | 18.40M | 3.98% | +1.1% |
| Vanguard Portfolio Management LLC | 12.28M | 2.65% | -14.7% |
| Geode Capital Management, LLC | 10.45M | 2.26% | +1.2% |
| Millennium Management Llc | 8.53M | 1.84% | -9.4% |
| Dimensional Fund Advisors LP | 6.24M | 1.35% | -3.4% |
| Palo Alto Investors Lp | 5.30M | 1.14% | -16.6% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of IOVA
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 13.49M | 2.91% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 11.25M | 2.43% |
| iShares Trust-iShares Russell 2000 ETF | 10.29M | 2.22% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 4.86M | 1.05% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 4.36M | 0.94% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 4.31M | 0.93% |
| iShares Trust-iShares Russell 2000 Value ETF | 3.73M | 0.81% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 3.08M | 0.67% |
| iShares Trust-iShares Biotechnology ETF | 3.07M | 0.66% |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 2.71M | 0.59% |
Frequently asked questions
Who is the largest shareholder of Iovance Biotherapeutics?
Blackrock Inc. is the largest institutional shareholder of IOVA, owning 8.19% of shares outstanding (37.90M shares) as of its latest 13F filing.
What percentage of Iovance Biotherapeutics is owned by institutions?
Institutions own about 69.2% of IOVA shares and 69.7% of the public float.
How much of Iovance Biotherapeutics do insiders own?
Insiders, such as officers and directors, own about 0.82% of IOVA shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.